ASCO
Strata Oncology Developing Integrated TMB, PD-L1, PD-L2 Test to Predict Checkpoint Inhibitor Benefit
Premium
The diagnostic company is confirming initial findings in a validation study and exploring companion diagnostic partnerships for the investigational test.
ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer
The guideline comes in the wake of the OlympiA trial results, which showed that the PARP inhibitor significantly improved invasive disease-free survival.
Lifileucel's BLA is again delayed, but a 33-month update from a pivotal melanoma trial, along with early data from a frontline study, show continued potential.
ASCO Studies Show Impact of Biomarker Testing, Therapy Inequities in Black Men With Prostate Cancer
Two studies highlighted the importance of enrolling Black men in clinical trials to improve outcomes and ensure the efficacy of treatments and tests
Molecular Profiling in Pediatric Cancer Trials Continues to Prove Valuable for Treatment Matching
Premium
The GAIN/iCat2 study and the Pediatric MATCH trial showed that molecular data has a significant impact on treatment recommendations for kids with cancer.